Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Harvard Catalyst Profiles is currently experiencing a partial system outage. Login/Edit modules are currently disabled.

Shuji Ogino, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Other Positions
Title
Institution
Department

Biography
2004
AMP Executive Officer's Award
2011
USCAP Ramzi Cotran Young Investigator Award
2012
AMP Meritorious Service Award
2014
Most Influential Scientific Minds
2014 - pres
ASCI Elected Member
2014 - pres
Member, FASEB Excellence in Science Award Committee
2015
Most Influential Scientific Minds
2015 - 2022
NCI Outstanding Investigator Award (OIA)
2016
Highly Cited Researcher
2017
Highly Cited Researcher
2018
ASIP Outstanding Investigator Award
2018
Highly Cited Researcher
2018
Runner-up for the Mentor-of-the-Year Award
2019 - 2021
Invited Nominator for Nobel Prize in Physiology or Medicine 2019, 2020, 2021
2019 - 2022
Highly Cited Researcher 2019, 2020, 2021

Overview
Dr. Ogino is Chief, Program in MPE Molecular Pathological Epidemiology of Department of Pathology, Brigham and Women's Hospital. He has been expanding the integrative interdisciplinary science of molecular pathological epidemiology (MPE). He is an Affilate Member of Broad Institute of MIT and Harvard. He has been serving as the Chair or Co-Chair for The International MPE Meeting Series since 2013 (www.mpemeeting.org).

Leveraging my unique interdisciplinary expertise, I have been developing transdisciplinary science of MPE (Ogino et al. J Natl Cancer Inst 2010; Gut 2011; Nat Rev Clin Oncol 2011; Epidemiology 2016; Annu Rev Pathol 2019) to unleash the full potential of the integrated research approach. Based on the paradigm of the seamlessly unified field of MPE, several new concepts and fields have emerged as below. Our proof-of-principle project utilized the prospective cohort design including a longitudinal exposure data collection integrated with data on colorectal cancer (CRC) incidence subtyped by a tumor tissue biomarker. That has been possible only with my establishment of a "prospective cohort incident tumor tissue biobank / database" of cancer cases that had occurred in prospective cohort studies. There were substantial challenges in establishing such a biobank, as incident tumors in the prospective cohort studies (the Nurses’ Health Study and Health Professionals Follow-up Study) had happened in different (U.S.-wide) geographic areas at variable unpredictable time points. There exist very few similar biobanks that have collected incident tumor tissue from persons who have developed tumors during prospective follow-up of a large population. My creation of the large-scale prospective cohort incident tumor tissue biobank is by itself a rare innovation that has enabled the novel style of studies.

Our proof-of-principle project utilized the prospective cohort design including a longitudinal exposure data collection integrated with data on colorectal cancer (CRC) incidence subtyped by a tumor tissue biomarker. Our first study (Chan et al. New Engl J Med 2007) successfully linked long-term aspirin use with decreased incidence of PTGS2-positive CRC and drew much attention. As of 2024 (17 years later), no other group has conducted a similar analysis.

We could also link long-term low folate intake with increased incidence of LINE-1 hypomethylated CRC (Schernhammer et al. Gut 2010). In the list of my innovations below, we also successfully linked high-level vitamin D status with decreased incidence of tumor-infiltrating lymphocyte (TIL)-high colorectal carcinoma (Song et al. Gut 2016). Furthermore, we could link the prudent diet pattern with decreased incidence of CRC containing abundant Fusobacterium nucleatum, a pathogenic bacterial species (Mehta et al. JAMA Oncol 2017). All of these and other MPE studies that examined tumor incidence (by subtypes) in relation to long-term exposure measures can be duly called “historical”. Despite the fact that these studies have drawn much attention, no other (very few if any) group has been able to conduct similar analyses using the prospective cohort design. My contribution to these scientific innovations has been unique and historical.

...

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R50CA274122 (UGAI, TOMOTAKA) Aug 30, 2023 - Jul 31, 2028
    NIH/NCI
    Integration of Immunology and Microbiology into Molecular Pathological Epidemiology of Colorectal Cancer
    Role: Research Unit Director
  2. DoD CA220816 (YU, KUN-HSING) Jul 1, 2023 - Jun 30, 2027
    Department of Defense
    Optimizing Individualized Colorectal Cancer Treatment and Prognostic Prediction via Causal Machine Learning
    Role: Co-Investigator
  3. R21CA252962 (ZHANG, XUEHONG) Aug 10, 2021 - Jul 31, 2024
    NIH
    Multidisciplinary Study of Folate Intake and Colorectal Cancer
    Role: Co-Investigator
  4. R01CA248857 (PETERS, ULRIKE) May 1, 2020 - Apr 30, 2026
    NIH
    Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer
    Role: Co-Principal Investigator
  5. Grand Challenge (MEYERSON, MATTHEW) Jan 1, 2019 - Apr 30, 2024
    Cancer Research UK
    Opportunity to Investigate the Microbiome's Impact on Science and Treatment in Colorectal Cancer (OPTIMISTICC)
    Role Description: No cost extension approved through December 2025.
    Role: Co-Leader of Work Package 2

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Updating...
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu. SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu.
Ogino's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (1126)
Explore
_
Co-Authors (219)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.